SCHEDULE 13G/A: Deep Track Capital Discloses 7.21% Stake in Nurix Therapeutics
Beneficial Ownership Report
Deep Track Capital, LP, along with its affiliated entities, has reported a beneficial ownership of 7.21% of Nurix Therapeutics, Inc.'s common stock as of March 31, 2025.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 5,500,000 shares of Nurix Therapeutics, Inc. common stock.
- This ownership represents 7.21% of the total outstanding common stock of Nurix Therapeutics, Inc.
- The calculation of the percentage of class is based on 76,235,594 common shares outstanding as of April 1, 2025, as reported in Nurix Therapeutics' 10-Q filing on April 8, 2025.
- The reporting persons share both voting power and dispositive power over all 5,500,000 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change in previously reported beneficial ownership.
- The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is mildly positive as it indicates a significant institutional investment, which can be viewed as a vote of confidence in the company, without any negative disclosures.
Positives
- The disclosure of a significant stake by an institutional investor like Deep Track Capital may signal confidence in Nurix Therapeutics' future prospects.
- Increased institutional ownership can sometimes lead to greater market stability and liquidity for the stock.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Nurix Therapeutics, Inc.'s future performance or strategic direction.
Industry Context
This filing reflects an institutional investment firm, Deep Track Capital, taking a significant passive stake in a biotechnology company. Such investments are common in the biotech sector, where specialized funds often identify promising companies for long-term holding, typically without seeking to influence control, as indicated by the 13G filing type.
Related Party Transactions
- David Kroin is identified as a control person for Deep Track Capital, LP, and also a director of Deep Track Biotechnology Master Fund, Ltd., indicating a related group of reporting persons acting in concert regarding this beneficial ownership.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may be perceived positively, potentially boosting investor confidence and attracting further investment interest.
- Company Management: Awareness of a large institutional holder may influence strategic decisions, though the 13G filing indicates a passive investment intent.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement (beneficial ownership threshold met). |
| 04/01/2025 | Date as of which the number of outstanding common shares (76,235,594) was determined for percentage calculation, per issuer's 10-Q. |
| 04/08/2025 | Date Nurix Therapeutics, Inc. filed its 10-Q with the SEC, providing the outstanding share count. |
| 05/15/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Nurix Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, NXAI
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.